Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.

Abstract

PURPOSE:

To clarify the efficacy of ranibizumab for treating age-related macular degeneration in patients with baseline visual acuity exceeding 20/40.

METHODS:

We retrospectively reviewed 40 eyes of Japanese patients with age-related macular degeneration (32 men, 8 women) treated with intravitreal injections of ranibizumab (0.5 mg/0.05 mL) (ranibizumab group). We compared the results with observation of 52 eyes (control group). All patients were followed-up for at least 12 months.

RESULTS:

In the ranibizumab group, the mean logarithm of the minimum angle of resolution best-corrected visual acuity (Snellen equivalent) with typical age-related macular degeneration (22 eyes) and polypoidal choroidal vasculopathy (18 eyes) statistically significantly (P < 0.0001, P = 0.015, respectively) improved from 0.17 (20/29) and 0.14 (20/28) at baseline to 0.07 (20/24) and 0.07 (20/24) at Month 12, respectively (mean numbers of treatments, 4.6 and 4.9). The central retinal thickness decreased from 262 ± 105 μm at baseline to 187 ± 62 μm at Month 12 in the ranibizumab group. In the control group, the mean logarithm of the minimum angle of resolution best-corrected visual acuity in eyes with typical age-related macular degeneration (19 eyes) and polypoidal choroidal vasculopathy (33 eyes) statistically significant (P = 0.017, P = 0.023, respectively) declined from 0.08 (20/24) and 0.10 (20/25) at baseline to 0.18 (20/30) and 0.23 (20/34) at Month 12, respectively.

CONCLUSION:

Intravitreal ranibizumab maintained or improved visual acuity and anatomic changes in patients with age-related macular degeneration with better than 20/40 visual acuity.

• Authors: Masaaki Saito, Tomohiro Iida, Mariko Kano
• Journal: Retina (Philadelphia, Pa.) (Retina) Vol. 32 Issue 7 Pg. 1250-9 (Jul 2012) ISSN: 1539-2864 [Electronic] United States
• PMID: 22446886 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Coloring Agents
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Indocyanine Green
• Ranibizumab

Topics

• Aged
• Aged, 80 and over
• Angiogenesis Inhibitors (administration & dosage)
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Coloring Agents
• Exudates and Transudates
• Female
• Fluorescein Angiography
• Follow-Up Studies
• Humans
• Indocyanine Green
• Intravitreal Injections
• Male
• Middle Aged
• Ranibizumab
• Retrospective Studies
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity (physiology)
• Wet Macular Degeneration (drug therapy, physiopathology)